Brukinsa is not a traditional chemotherapy drug. It belongs to a newer class of cancer treatments called targeted therapies, specifically kinase inhibitors. While chemotherapy works by killing rapidly dividing cells throughout the body (both cancerous and healthy), Brukinsa zeroes in on a single protein that certain blood cancers need to grow. This distinction matters because it changes what treatment feels like day to day and what side effects you can expect.
How Brukinsa Differs From Chemotherapy
Traditional chemotherapy drugs are cytotoxic, meaning they poison cells during division. That’s why chemo causes hair loss, severe nausea, and immune suppression: it can’t distinguish between a cancer cell dividing and a healthy cell dividing. Brukinsa (generic name: zanubrutinib) takes a fundamentally different approach. It blocks a specific enzyme called Bruton’s tyrosine kinase, or BTK, which acts as a growth signal for certain white blood cells called B cells.
In many blood cancers, B cells multiply out of control because this signaling pathway is stuck in the “on” position. Brukinsa attaches permanently to the active site of BTK, shutting the signal down. In clinical testing, the drug blocked more than 95% of BTK activity in patients’ blood cells. Without that growth signal, the cancerous B cells stop proliferating and eventually die off.
Because it targets one specific protein rather than all dividing cells, Brukinsa spares most healthy tissue. You won’t lose your hair on Brukinsa, and severe nausea isn’t a typical side effect. That said, “targeted” doesn’t mean “side-effect-free,” and the drug does carry its own set of risks.
What Brukinsa Is Approved to Treat
The FDA has approved Brukinsa for several B-cell blood cancers in adults:
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Waldenström’s macroglobulinemia (WM)
- Mantle cell lymphoma (MCL) after at least one prior treatment
- Marginal zone lymphoma (MZL) after at least one prior treatment that included a certain type of antibody therapy
- Follicular lymphoma (FL) in combination with another drug, after two or more prior treatments
All of these are cancers of B cells, which is why a BTK inhibitor works across several diagnoses. The common thread is that abnormal B-cell signaling drives the disease.
How You Take It
One of the biggest practical differences from chemotherapy is how Brukinsa is administered. There are no infusion appointments or IV lines. Brukinsa comes as capsules you swallow at home, either 160 mg twice a day or 320 mg once a day, with or without food. You take it continuously, every day, until the cancer progresses or side effects become intolerable. For many patients with CLL, that means staying on Brukinsa for years.
This open-ended treatment timeline is another contrast with traditional chemo, which typically runs for a set number of cycles (often four to six rounds over several months). With Brukinsa, as long as it’s working and you’re tolerating it, you keep taking it.
How Well It Works
In patients with CLL or SLL who had previously tried other BTK inhibitors, 64% achieved a partial or complete response to Brukinsa, and 94% experienced some degree of disease control. The two-year progression-free survival rate was 76%, meaning roughly three out of four patients had no disease worsening after two years on the drug. For a cancer that often requires lifelong management, those numbers are significant.
Side Effects Compared to Chemo
Brukinsa’s side effect profile looks quite different from what most people associate with chemotherapy. Across a pooled group of 1,550 patients in clinical trials, the most common issues were:
- Low neutrophil counts (42%), a drop in a type of white blood cell that fights infection
- Upper respiratory tract infections (39%), such as colds and sinus infections
- Low platelet counts (34%), which can make bruising and bleeding easier
- Bleeding events (30%), ranging from nosebleeds to more serious hemorrhage
- Musculoskeletal pain (30%), including joint and muscle aches
You’ll notice what’s missing from that list: the hallmark chemo side effects like hair loss, severe vomiting, and mouth sores. The trade-off is a different set of concerns. The drop in neutrophils and platelets means your body may have a harder time fighting infections and stopping bleeding. If you’re on Brukinsa, your care team will monitor your blood counts regularly and may adjust your dose if levels drop too low.
Bleeding risk deserves particular attention. Because BTK plays a role in platelet function, Brukinsa can increase the tendency to bleed. This is especially relevant if you take blood thinners or need surgery. Most bleeding events are minor, but serious cases do occur.
Where Brukinsa Fits in Cancer Treatment
Brukinsa belongs to a generation of drugs that has reshaped how blood cancers are treated. Before BTK inhibitors became available, many patients with CLL and similar cancers relied on chemotherapy combinations that were effective but came with harsh side effects and limited durability. BTK inhibitors offered a way to control these diseases long-term with a daily pill and a more manageable side effect profile.
Brukinsa is the second-generation version of this approach. The first widely used BTK inhibitor, ibrutinib, blocked BTK but also hit several other enzymes, contributing to side effects like heart rhythm problems and high blood pressure. Brukinsa was designed to be more selective, binding more precisely to BTK and leaving other enzymes largely alone. In clinical trials, patients who couldn’t tolerate earlier BTK inhibitors often did well after switching to Brukinsa.
So while your oncologist might use the word “chemotherapy” loosely to describe any cancer drug, Brukinsa is technically and practically a different category of treatment. It’s a targeted oral therapy that blocks one protein driving cancer growth, taken daily at home, with a side effect profile that reflects its precision rather than the broad-cell-killing approach of traditional chemo.